Skinvisible, Inc. - Form 8-K

0001663577-24-000143.txt : 20240529 0001663577-24-000143.hdr.sgml : 20240529 20240529133522 ACCESSION NUMBER: 0001663577-24-000143 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINVISIBLE, INC. CENTRAL INDEX KEY: 0001085277 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880344219 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25911 FILM NUMBER: 24996778 BUSINESS ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: UNIT 9 CITY: LAS VEGAS STATE: NV ZIP: 89120 BUSINESS PHONE: 702-433-7154 MAIL ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: UNIT 9 CITY: LAS VEGAS STATE: NV ZIP: 89120 FORMER COMPANY: FORMER CONFORMED NAME: SKINVISIBLE INC DATE OF NAME CHANGE: 19990428 8-K 1 skvi8k052924.htm FORM 8-K Skinvisible, Inc. - Form 8-K - May 29, 2024

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 29, 2024

Skinvisible, Inc.
(Exact name of registrant as specified in its charter)

Nevada

000-25911

88-0344219

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)


6320 South Sandhill Road Suite 9, Las Vegas, NV	89120
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 702-433-7154

___________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	[ ]	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

	[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

SECTION 7 – Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure

On May 29, 2024, we issued a press release concerning the filing of our Provisional Patent Application with the US Patent & Trademark Office entitled “Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," covering formulations that leverage our proprietary delivery technology Invisicare for the transdermal administration of obesity drugs, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release, dated May 29, 2024

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Skinvisible, Inc.

/s/ Terry Howlett

Terry Howlett
Chief Executive Officer

Date: May 29, 2024

3

EX-99.1 2 ex99_1.htm PRESS RELEASE, DATED MAY 29, 2024

FOR IMMEDIATE RELEASE

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System

LAS VEGAS, NV – May 29, 2024 – Skinvisible Pharmaceuticals, Inc. (“Skinvisible” or “the Company”), (OTCQB: SKVI), an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity. The Company has achieved a significant milestone by officially filing a provisional patent application covering formulations that leverage the Company's proprietary delivery technology Invisicare® for the transdermal administration of obesity drugs. Titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," this patent filing ushers in a new era of efficient and convenient obesity drug delivery solutions.

The patent application focuses on Invisicare; a patented transdermal delivery technology designed to incorporate CB-1 receptor antagonists and/or GPL-1 receptor agonists, two classes of drugs known for their potential in obesity management, into a lotion that is applied topically to the skin using a metered applicator. Studies have demonstrated the superior transdermal penetration and controlled release of other active compounds using Invisicare's innovative technology; with certain actives exhibiting up to a tenfold increase in transdermal delivery effectiveness. By utilizing Invisicare, Skinvisible aims to not only offer patients a convenient and effective alternative to traditional oral or injectable therapies but to also enhance drug efficacy and potentially significantly reduce side effects as transdermal delivery avoids first-pass metabolism. Additionally, for long-term treatment of obesity, a transdermal delivery system could feasibly provide a convenient method for administering maintenance doses of anti-obesity medications.

The global obesity drug market is poised to exceed $30 billion by 2027, propelled by the escalating prevalence of obesity worldwide and the eagerly anticipated advent of revolutionary anti-obesity medications. Nonetheless, the impediment posed by needles and injections remains a formidable barrier to access and compliance. Skinvisible's proprietary transdermal delivery technology overcomes this obstacle, unlocking the full therapeutic potential of CB-1 and GLP-1 targeting drugs.

"Our transdermal technology has the potential to revolutionize how obesity drugs are administered, granting patients access to potent weight loss medications through the ease and convenience of a metered dose of lotion simply applied to the skin," remarked Terry Howlett, CEO of Skinvisible Pharmaceuticals. "This needle-free approach holds immense promise in enhancing treatment adherence and broadening the accessibility of obesity therapies to countless individuals grappling with weight-related challenges." He added, “This groundbreaking patent application highlights our proficiency in transdermal delivery and underscores our commitment to leveraging this capability to reshape treatment standards.”

Skinvisible is actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to facilitate the introduction of the first transdermal obesity therapies to market and to explore the application of its delivery platform across diverse disease domains.

For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2024).

###

Contacts:

·

Strategic Partnerships: Doreen McMorran - doreen@invisicare.com

·

Corporate Inquiries: info@skinvisible.com

·

Office Number: 702-433-7154 (PST)

2

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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skvi-20240529.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 skvi-20240529_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 skvi-20240529_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 29, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 29, 2024
Entity File Number	000-25911
Entity Registrant Name	Skinvisible, Inc.
Entity Central Index Key	0001085277
Entity Tax Identification Number	88-0344219
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6320 South Sandhill Road
Entity Address, Address Line Two	Suite
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89120
City Area Code	702
Local Phone Number	433-7154
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://skinvisible.com/role/Cover Cover Cover 1 false false All Reports Book All Reports skvi-20240529.xsd skvi-20240529_lab.xml skvi-20240529_pre.xml skvi8k052924.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skvi8k052924.htm": { "nsprefix": "SKVI", "nsuri": "http://skinvisible.com/20240529", "dts": { "schema": { "local": [ "skvi-20240529.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "skvi-20240529_lab.xml" ] }, "presentationLink": { "local": [ "skvi-20240529_pre.xml" ] }, "inline": { "local": [ "skvi8k052924.htm" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 20 }, "report": { "R1": { "role": "http://skinvisible.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "skvi8k052924.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "skvi8k052924.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://skinvisible.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001663577-24-000143-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001663577-24-000143-xbrl.zip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end XML 18 skvi8k052924_htm.xml IDEA: XBRL DOCUMENT 0001085277 2024-05-29 2024-05-29 iso4217:USD shares iso4217:USD shares false 0001085277 8-K 2024-05-29 Skinvisible, Inc. NV 000-25911 88-0344219 6320 South Sandhill Road Suite Las Vegas NV 89120 702 433-7154 false false false false false